Remote monitoring with the Reveal Linq insertable cardiac monitor can improve outcomes without breaking the bank, according to new data being presented at the International Stroke Conference in Phoenix.

One of the world's leading heart hospitals is seeing significant growth. This represents the first time it has hired four new cardiothoracic surgeons in a single 12-month period. 

Researchers explored the potential of an alternate way to perform PFA on patients with persistent AFib, presenting their findings live at AF Symposium 2024 in Boston.

The approval, based on positive results from the TRISCEND II trial, represents a significant milestone for the treatment of severe tricuspid regurgitation. 

Heart teams have several options when patients present with stable chest pain and require further testing. According to a brand new analysis of nearly 800 patients, CCTA may be the best place to start. 

New research out of Texas could go a long way toward improving care for patients with acute decompensated heart failure.

The FDA’s final decision was based largely on positive results from the ADVENT clinical trial, which compared treatment with the Farapulse PFA System to the current standard of care.

Annual SAVR volumes in the United States decreased by a whopping 44.5% from 2012 to 2022. However, heart teams across the country seem to agree that surgery is a safer, more effective treatment option than TAVR when patients present with bicuspid aortic valves.